Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCLINASDAQ:CELZNASDAQ:SLXNNASDAQ:UPTD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$1.22+8.0%$1.09$0.72▼$8.09$9.69M0.24363,124 shs517,039 shsCELZCreative Medical Technology$2.39+6.2%$2.05$1.69▼$6.90$6.19M1.9852,725 shs101,568 shsSLXNSilexion Therapeutics$0.95+2.6%$0.91$0.58▼$41.85$8.22M0.125.06 million shs258,079 shsUPTDTradeUP Acquisition$1.07+0.5%$1.51$6.88▼$33.00$2.31M0.12270,115 shs70,743 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics0.00%+6.11%+0.74%-26.06%-81.37%CELZCreative Medical Technology0.00%+9.13%+14.35%-42.41%-46.05%SLXNSilexion Therapeutics0.00%-7.27%-4.84%-28.89%+94,579,900.00%UPTDTradeUP Acquisition+0.48%+5.50%-4.90%+7.80%+12.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCLIBrainstorm Cell Therapeutics4.2939 of 5 stars3.55.00.04.71.70.80.6CELZCreative Medical Technology1.2611 of 5 stars0.05.00.00.02.20.01.3SLXNSilexion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AUPTDTradeUP AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCLIBrainstorm Cell Therapeutics 3.00Buy$30.002,359.02% UpsideCELZCreative Medical Technology 0.00N/AN/AN/ASLXNSilexion Therapeutics 3.00Buy$5.00428.65% UpsideUPTDTradeUP Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest UPTD, CELZ, SLXN, and BCLI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/20/2025SLXNSilexion TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $5.00(Data available from 6/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.20) per shareN/ACELZCreative Medical Technology$14K441.47N/AN/A$7.48 per share0.32SLXNSilexion TherapeuticsN/AN/A$0.65 per share1.46($6.63) per shareN/AUPTDTradeUP AcquisitionN/AN/AN/AN/A($1.59) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCLIBrainstorm Cell Therapeutics-$17.19M-$3.36N/AN/AN/AN/AN/A-528.56%8/13/2025 (Estimated)CELZCreative Medical Technology-$5.29M-$3.81N/AN/AN/AN/A-63.05%-60.42%8/8/2025 (Estimated)SLXNSilexion Therapeutics$260KN/A0.00∞N/AN/AN/A-249.43%6/17/2025 (Estimated)UPTDTradeUP Acquisition-$1MN/A0.00∞N/AN/AN/A-3.38%N/ALatest UPTD, CELZ, SLXN, and BCLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025BCLIBrainstorm Cell Therapeutics-$0.38-$0.45-$0.07-$0.45N/AN/A5/13/2025N/ASLXNSilexion TherapeuticsN/A-$0.26N/A-$0.26N/AN/A5/9/2025Q1 2025CELZCreative Medical Technology-$0.52-$0.83-$0.31-$0.83N/A$0.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ACELZCreative Medical TechnologyN/AN/AN/AN/AN/ASLXNSilexion TherapeuticsN/AN/AN/AN/AN/AUPTDTradeUP AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCLIBrainstorm Cell TherapeuticsN/A0.050.05CELZCreative Medical TechnologyN/A19.1319.12SLXNSilexion TherapeuticsN/A0.850.85UPTDTradeUP AcquisitionN/A0.090.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCLIBrainstorm Cell Therapeutics14.33%CELZCreative Medical Technology1.42%SLXNSilexion Therapeutics10.95%UPTDTradeUP Acquisition34.95%Insider OwnershipCompanyInsider OwnershipBCLIBrainstorm Cell Therapeutics11.15%CELZCreative Medical Technology2.80%SLXNSilexion Therapeutics33.00%UPTDTradeUP Acquisition55.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCLIBrainstorm Cell Therapeutics407.94 million5.32 millionOptionableCELZCreative Medical Technology52.59 million1.70 millionNot OptionableSLXNSilexion TherapeuticsN/A8.69 million1.07 millionN/AUPTDTradeUP Acquisition2,0212.17 million973,000Not OptionableUPTD, CELZ, SLXN, and BCLI HeadlinesRecent News About These CompaniesEstrella Immunopharma stock plunges in market debut after SPAC mergerOctober 2, 2023 | msn.comSPAC TradeUp, Estrella Biopharma complete merger; shares to debut Oct. 2September 29, 2023 | msn.comTradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business CombinationSeptember 29, 2023 | finance.yahoo.comTradeUP (UPTD) Stock is Up: What's Going On?September 21, 2023 | benzinga.comTradeUp (NASDAQ: UPTD) up 67% - Hey, maybe a deal really will be done hereSeptember 15, 2023 | dhakatribune.comWhy TradeUP Acquisition (UPTD) Stock Is Rocketing HigherSeptember 1, 2023 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUPTD, CELZ, SLXN, and BCLI Company DescriptionsBrainstorm Cell Therapeutics NASDAQ:BCLI$1.22 +0.09 (+7.96%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$1.20 -0.02 (-1.64%) As of 06/6/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Creative Medical Technology NASDAQ:CELZ$2.39 +0.14 (+6.22%) Closing price 06/6/2025 03:58 PM EasternExtended Trading$2.34 -0.05 (-2.13%) As of 06/6/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.Silexion Therapeutics NASDAQ:SLXN$0.95 +0.02 (+2.64%) Closing price 06/6/2025 03:56 PM EasternExtended Trading$0.92 -0.02 (-2.20%) As of 06/6/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.TradeUP Acquisition NASDAQ:UPTDTradeUP Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later? MongoDB Affirms Outlook and Accelerates Stock Price Reversal Five Below Pops on Strong Earnings, But Rally May Stall Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
